Menu Search
Equities

Denali Therapeutics Inc

4DN:FRA

Denali Therapeutics Inc

Actions
  • Price (EUR)27.29
  • Today's Change-0.01 / -0.04%
  • Shares traded100.00
  • 1 Year change+38.32%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Denali Therapeutics Inc grew revenues 204.74% from 108.46m to 330.53m while net income improved from a loss of 325.99m to a smaller loss of 145.22m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-31.77%
Return on equity-35.09%
Return on investment-33.76%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Denali Therapeutics Inc fell by 90.86m. However, Cash Flow from Investing totalled 249.31m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 357.99m for operations while cash generated from financing totalled 17.82m.
Cash flow per share-2.68
Price/Cash flow per share--
Book value per share9.17
Tangible book value per share9.17
More ▼

Balance sheet in USDView more

Denali Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio9.98
Quick ratio--
Total debt/total equity0.0043
Total debt/total capital0.0043
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.